^
    Back
    Association details:
    Biomarker:EGFR L747P
    Cancer:Lung Adenocarcinoma
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Thorac Cancer
    Title:

    Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

    Published date:
    09/21/2021
    Excerpt:
    ...the effectiveness of afatinib in patients with stage IIIB/IV lung adenocarcinoma...Afatinib demonstrated clinical activity across a set type of specific rare uncommon mutations, including EGFR L747P, A767_V769dup, and L833V/H835L...Our findings suggested that afatinib is effective in patients with uncommon mutations.
    DOI:
    10.1158/2159-8290.CD-21-0715
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma

    Published date:
    06/03/2021
    Excerpt:
    Eighty-four organoids were established from patients with advanced lung adenocarcinoma….YUO-004 and YUO-050 harboring an EGFR L747P mutation was sensitive to afatinib…
    DOI:
    10.1158/1078-0432.CCR-20-5026